Други Новости Promediкa Ophthalmology introduced the first and most modern laser in the country for retinological diseases
Eylea 8mg: Injections that save vision
Promedica Ophthalmology has taken its first step in implementing the latest therapy Eylea 8mg, an advanced drug for the treatment of retinological diseases. Today, Dr. Zlatko Chipurovski administered this revolutionary new drug to two patients, which represents a significant moment for our hospital.
What is Eylea 8mg and who is it for?
Eylea 8mg is the latest version of this already well-known and proven drug that is used to treat retinological eye conditions such as wet macular degeneration and diabetic retinopathy. These conditions often lead to significant vision loss if not treated properly and promptly. Eylea 8mg is intended for patients who are facing these diseases and are looking for an effective treatment that provides long-term protection of their vision.
How does Eylea 8mg work?
Compared to Eylea, the drug that we have been administering to patients for years, Eylea 8mg differs in that it has a higher concentration, which allows for less frequent application. Patients can get longer-lasting protection with fewer injections, making treatment more comfortable and effective. This drug works by blocking proteins that cause abnormal blood vessel growth in the eye, thereby preventing damage to the retina and improving or stabilizing vision.
Application in Promedica Ophthalmology
Today’s application of Eylea 8mg by Dr. Zlatko Chipurovski is an important step in Promedika Ophthalmology’s efforts to provide cutting-edge therapies to its patients. This advancement not only improves the quality of life of patients, but also positions our services as a leader in ophthalmology.
We are proud to offer our patients access to the latest medical advances and will continue to invest in their care and health.